Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 73.06 percent increase over losses of $(1.93) per share from the same period last year. The company reported quarterly sales of $17.993 million which beat the analyst consensus estimate of $17.346 million by 3.73 percent. This is a 20.85 percent decrease over sales of $22.733 million the same period last year.
Aytu BioPharma Q3 2024 GAAP EPS $(0.52) Beats $(0.64) Estimate, Sales $17.993M Beat $17.346M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.